We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Magnetic Nanoparticles Detect Cancerous Cells in Breast Tissue Samples

By Labmedica staff writers
Posted on 10 Mar 2008
A new medical device based on biomagnetics will make the early detection of breast cancer more cost-effective and easier to administer. More...
Consisting of magnetic nanoparticles and an extremely sensitive magnetometer, it will detect cancerous cells in samples of breast tissue.

By automating the process through which cancerous cells are detected and quantified, the new device, which is called HistoMag, will not only ease the pressure on pathologists but also help to identify the 15-30% of patients who are likely to benefit from being treated with the drug Herceptin.

A team of scientists from University College London (UCL; UK) developed HistoMag. "At UCL we [have] been working in the relatively new area of biomagnetics to develop a technique that provides more quantitative and reliable results, whilst also enabling pathologists to identify abnormal tissue sections much more quickly,” said Prof. Quentin Pankhurst of the London Center for Nanotechnology (LCN, London, UK) and the UCL department of physics and astronomy.

"Cancerous cells have a protein on their surface called HER2. We use a solution of HER2 antibodies, tagged with magnetic nanoparticles, to stain the tissue sample. Using the HistoMag we can detect the quantity of tagged antibodies which attach themselves to the HER2 protein, which in turn provides us with an accurate picture of the spread of cancerous cells” Prof. Pankhurst added.

According to Prof. Pankhurst, pathologists have had to stain tissue samples with brown dyes to help them determine whether they are normal or cancerous. The main problem with this is that all of the results are open to interpretation, and each test has to be individually checked by a specialist.

The team at UCL, led by Prof. Pankhurst, is one of seven groups to receive a Brian Mercer Feasibility Award from the Royal Society this year. The UK£25,000 award will enable the team to reengineer the HistoMag, increasing its sensitivity before it goes on to clinical trials. The goal is to make the device generally available to pathologists in 2010.


Related Links:
University College London
London Center for Nanotechnology

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.